Company / Shareholders' Equity
Larimar Therapeutics, Inc. Shareholders' Equity History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$93.3M
FY2019
5-year range
-$68.6M / $169.1M
FY2015-FY2019
Trend
-23.4%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $169M to $93M over the past 2 years.
Based on SEC 10-K filings.
$93M in FY2019 with a 3-year CAGR of -3.7%.
Declined from $169M to $93M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -3.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -3.7%, indicating a declining trend.
- In FY2019, shareholders' equity decreased 23.4% year-over-year.
- Peak shareholders' equity was recorded in FY2017.
- Lowest shareholders' equity in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $93.3M | -23.4% |
| FY2018 | $121.7M | -28.0% |
| FY2017 | $169.1M | +61.9% |
| FY2016 | $104.4M | +252.3% |
| FY2015 | -$68.6M | -25.3% |
| FY2014 | -$54.7M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026